June 18 (Reuters) - 2cureX AB 2CUREX.ST :
* SAID ON MONDAY IT INDENDS TO EXECUTE DIRECTED ISSUE OF 7.5
MILLION SHARES TO CONSORTIUM LED BY KINLED GROUP,
HONG-KONG-BASED PRIVATE INVESTMENT COMPANY
* FUNDS RAISED WILL BE USED TO ESTABLISH NOVEL COMMERCIAL
MODEL
AIMED AT PROVIDING FUNCTIONAL PRECISION ONCOLOGY SERVICES
* SECURED LOAN OF 3 MILLION EUROS FROM CONSORTIUM TO FURTHER
DEVELOP 2CUREX AB WITHIN FUNCTIONAL PRECISION ONCOLOGY
* WILL ABORT DELISTING PROCESS AND WILL CONTINUE TO HAVE
SHARES
TRADED ON NASDAQ FIRST NORTH GROWTH MARKET IN STOCKHOLM
* RECEIVED AND ACCEPTED OFFER TO SELL DANISH SUBSIDIARY,
2CUREX
A/S, TO CONSORTIUM COMPRISING CURRENT SHAREHOLDERS OF 2CUREX AB
AND KINLED GROUP
* RESOLVED TO DISTRIBUTE PROCEEDS FROM SALE OF 2CUREX A/S
PROPORTIONALLY TO ALL 2CUREX AB SHAREHOLDERS
* SALE PRICE IS SET AT VWAP FOR 2CUREX AB OF PRECEDING 10
TRADING
DAYS, PLUS 10% PREMIUM, AMOUNTING TO 0.32 SEK PER SHARE
Source text for Workspace: urn:newsml:reuters.com:*:nMFN4r1nJp
Further company coverage: 2CUREX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))